Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Chesapeake Capital Corp IL

Chesapeake Capital Corp IL grew its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 49.3% during the 4th quarter, HoldingsChannel reports. The firm owned 24,638 shares of the biotechnology company’s stock after buying an additional 8,138 shares during the period. Chesapeake Capital Corp IL’s holdings in Grifols were worth $183,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Atria Investments Inc purchased a new position in shares of Grifols during the 3rd quarter worth $344,000. Oppenheimer Asset Management Inc. raised its holdings in shares of Grifols by 5.0% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 58,677 shares of the biotechnology company’s stock worth $521,000 after acquiring an additional 2,790 shares during the period. Natixis Advisors LLC raised its holdings in shares of Grifols by 40.0% during the 3rd quarter. Natixis Advisors LLC now owns 215,667 shares of the biotechnology company’s stock worth $1,915,000 after acquiring an additional 61,614 shares during the period. Anthracite Investment Company Inc. purchased a new position in shares of Grifols during the 3rd quarter worth $5,457,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Grifols by 7.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 31,543 shares of the biotechnology company’s stock worth $280,000 after acquiring an additional 2,301 shares during the period.

Wall Street Analyst Weigh In

Separately, Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Price Performance

NASDAQ GRFS opened at $8.10 on Wednesday. The firm has a market cap of $5.57 billion, a PE ratio of 6.92 and a beta of 0.35. Grifols, S.A. has a 52 week low of $5.79 and a 52 week high of $9.96. The business’s fifty day simple moving average is $7.51 and its 200-day simple moving average is $8.11. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.